Global News

Accera, University of Miami to study Axona for cognitive impairment in MS

Wednesday, April 10, 2013 10:44 AM

Accera, a privately-held, commercial-stage healthcare company focused on clinical applications to address acute and chronic neurodegenerative diseases, has formed a collaboration with the University of Miami Miller School of Medicine to study the effects of Accera's medical food, Axona, on cognitive impairment in patients with multiple sclerosis (MS).

More... »

IOM to develop consensus study on strategies for sharing clinical trial data

Wednesday, April 10, 2013 09:46 AM

The Institute Of Medicine (IOM) plans to follow up on its recent workshop, Sharing Clinical Research Data, by developing a consensus study on strategies for sharing clinical trial data.

More... »

Unigene secures financing to extend operations, cuts 40% of staff

Tuesday, April 9, 2013 08:00 AM

Unigene Laboratories, a biopharmaceutical company focused on peptide-based therapeutics, has entered into a second amendment to a financing agreement with affiliates of Victory Park Capital Advisors (VPC), whereby VPC has agreed to purchase an additional $750,000 senior secured note, providing Unigene with additional working capital.

More... »

BMS appoints Francis Cuss as executive vice president, CSO

Monday, April 8, 2013 03:00 PM

Bristol-Myers Squibb, a global biopharmaceutical company, has appointed Francis Cuss, MB, BChir, FRCP, as executive vice president and chief scientific officer, effective July 1 after Elliott Sigal, M.D., Ph.D., retires.

More... »

Roche, Isis Pharmaceuticals form alliance for Huntington's disease

Monday, April 8, 2013 02:29 PM

Basel, Switzerland-based Roche and Isis Pharmaceuticals of Carlsbad, Calif., have formed an alliance to develop treatments for Huntington's disease (HD) based on Isis' antisense oligonucleotide (ASO) technology.

More... »

Merz Pharma Group withdraws proposal to acquire Obagi

Monday, April 8, 2013 02:01 PM

Merz Pharma Group has withdrawn its non-binding proposal to acquire all of the outstanding common stock of Obagi Medical Products for $22 per share in cash.

More... »

Frazier Healthcare acquires AndersonBrecon

Monday, April 8, 2013 12:03 PM

Frazier Healthcare, a provider of growth equity and venture capital to emerging healthcare service and biopharma companies, has signed a definitive agreement to acquire AndersonBrecon, a contract pharmaceutical packaging business and wholly owned subsidiary of AmerisourceBergen. 

More... »

LabCorp Clinical Trials selected as preferred provider by BMS

Monday, April 8, 2013 11:05 AM

Laboratory Corporation of America Holdings (LabCorp) announced that LabCorp Clinical Trials has been selected as a preferred provider for full-service global central laboratory services and biomarker testing by Bristol-Myers Squibb.

More... »

inVentiv Health sells sample management business to J. Knipper

Monday, April 8, 2013 10:36 AM

J. Knipper and Company, a provider of healthcare marketing solutions, has acquired the inVentiv Health MySTRO Sample Management and Fulfillment business, including regulatory compliance, sample accountability and fulfillment services.

More... »

AstraZeneca touts top-line results from OSKIRA-1 phase III study of fostamatinib in RA

Friday, April 5, 2013 12:33 PM

AstraZeneca released top-line results of OSKIRA-1, a phase III study to assess the efficacy and safety of fostamatinib, the first oral spleen tyrosine kinase (SYK) inhibitor in development for rheumatoid arthritis (RA). OSKIRA-1 had two primary endpoints: assessing signs and symptoms of RA as measured by ACR20 response rates, and an X-ray endpoint known as mTSS (modified Total Sharp Score).

More... »